Congo's Ebola outbreak just spread to two new provinces, and here's the problem: the approved vaccines don't work against this strain. Oxford is racing to change that with the first-ever human trial of a Bundibugyo-specific vaccine, built on the same platform as the AstraZeneca COVID shot.
A Body on a Motorcycle
A pregnant woman fell ill in Bunia, a bustling city in the Democratic Republic of Congo's Ituri Province. She died on June 27. Her body was strapped to a motorcycle and driven roughly 300 kilometers west to Kisangani, the capital of Tshopo Province. At the morgue, a sample tested positive for Ebola.
That single journey captures everything terrifying about this outbreak. The virus is hitching rides across provinces, carried by people fleeing for care, mourning their dead, or simply trying to escape. And the worst part? There's no approved vaccine for this strain of Ebola.
Not anymore, though. Oxford just fired the starting gun.
The Wrong Kind of Ebola
When most people hear "Ebola," they think of the Zaire strain, the one behind the devastating 2014 West Africa epidemic. That's the strain with a blockbuster vaccine: Merck's Ervebo, which has been used in outbreaks for years.
But Ebola isn't one virus. It's a family. And the strain tearing through eastern Congo right now is Bundibugyo ebolavirus, a rarer cousin first identified in Uganda back in 2007. Think of it like this: if Zaire Ebola is the flu strain your flu shot was designed for, Bundibugyo is the one that mutated just enough to slip past your defenses.
That analogy isn't hypothetical. WHO has explicitly advised against using Ervebo for Bundibugyo patients. In an animal study, Ervebo showed roughly 75% effectiveness against Bundibugyo, with three out of four monkeys surviving, but "might work" isn't good enough when people are dying. And the other licensed Ebola vaccine, Johnson & Johnson's Zabdeno/Mvabea two-dose regimen? The European Commission withdrew its authorization in May 2026 at the manufacturer's request. Commercial reasons, apparently.
So the world is fighting a major Ebola outbreak with zero approved vaccines and zero approved treatments for this specific virus. The playbook is old school: isolate patients, trace contacts, bury the dead safely, and hope your health workers don't get infected. Four health workers died in the very first cluster.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Numbers Are Ugly
As of July 11, Congo has tallied 1,926 confirmed cases and 702 deaths across five provinces. Ituri remains the epicenter, accounting for 1,745 cases alone across 26 of the province's 36 health zones. South Kivu, Haut-Uele, and Tshopo round out the list with smaller but deeply concerning numbers.
The spread to Tshopo and Haut-Uele is what has epidemiologists on edge. All the cases in those provinces trace back to Ituri, meaning people are carrying the virus outward along roads and rivers before anyone can stop them. Haut-Uele borders both South Sudan and the Central African Republic. Tshopo's capital, Kisangani, is a major transportation hub.
Uganda has confirmed 20 cases and 2 deaths of its own, making this a cross-border crisis. WHO declared a Public Health Emergency of International Concern (PHEIC) back on May 17, rating national risk in Congo as "very high" and regional risk as "high." Treatment centers in some areas are running at 90% capacity.
The outbreak originated in Mongbwalu, a gold mining town in Ituri with constant flows of workers and traders. It's the worst possible setting for containment: high traffic, informal housing, and limited health infrastructure.
Oxford's Big Bet
Enter the University of Oxford's Vaccine Group, which just launched the first-ever human trial of a Bundibugyo-specific Ebola vaccine. The trial, called BD-Ebov, will test a vaccine called ChAdOx1 BDBV in 50 healthy adults aged 18 to 55 in Oxford, UK.
If that "ChAdOx" prefix sounds familiar, it should. This is the same viral vector platform behind the Oxford/AstraZeneca COVID-19 vaccine that went into hundreds of millions of arms during the pandemic. The technology uses a harmless chimpanzee cold virus to deliver Bundibugyo-specific proteins to human cells, training the immune system to recognize the real thing. Crucially, it cannot cause Ebola.
The trial follows a careful, stepwise design. The first 10 volunteers get vaccinated and are monitored closely before the remaining 40 are enrolled. Primary goals: figure out if it's safe, and measure the immune response it triggers.
Speed is the theme here. Oxford submitted its application to UK regulators on June 24. The ethics committee turned it around in five days. The medicines regulator (MHRA) ran a parallel review. Total time from submission to green light: under three weeks. That's the fast-track system working exactly as designed.
Manufacturing is already ahead of the science. The Serum Institute of India produced roughly 620,000 doses within two weeks and supplied 4,000 investigational doses for the trial. If Phase I results look good, additional trials in Uganda are already being planned with local research partners.
A Three-Horse Race
Oxford's ChAdOx1 vaccine isn't the only Bundibugyo candidate in development. CEPI, the global epidemic preparedness coalition, is backing three platforms simultaneously:
The rVSV Bundibugyo vaccine from IAVI uses the same technology as Ervebo but swaps in the Bundibugyo protein. WHO experts called it "the most promising" candidate in May, but it's further from human trials, likely 7 to 9 months away. Moderna is working on an mRNA version, still in preclinical stages.
Oxford's advantage is time. Regulators estimated their vaccine could be ready for efficacy assessment within 2 to 3 months, the fastest of the three. The tradeoff: adenovirus-based vaccines like ChAdOx1 may need two doses for some populations, which complicates outbreak logistics. Single-dose convenience is part of what made Ervebo so effective in the field.
On the treatment side, a pan-ebolavirus antibody cocktail called MBP-134 from Mapp Biopharmaceutical shows activity against multiple Ebola species, including Bundibugyo. Remdesivir is also being considered. But treatments help after infection; vaccines stop it from happening.
Why This Matters Beyond Congo
Bundibugyo ebolavirus has a historical case-fatality rate of roughly 30 to 50%. That's lower than classic Zaire Ebola (which can reach 80 to 90%), but "only" killing a third of the people it infects is not exactly reassuring.
The deeper lesson is about preparedness gaps. The world invested billions to build Ebola vaccines after the 2014 catastrophe, and it worked beautifully for Zaire. But when a different member of the Ebola family showed up, the cupboard was bare. Standard rapid tests designed for Zaire can miss Bundibugyo infections entirely, which means cases may go undetected for days in the field.
WHO officials have said they're "catching up" in the response, a phrase that should make everyone uncomfortable. Catching up means the virus had a head start.
Oxford's trial won't produce results overnight. But 620,000 doses sitting in a warehouse, a Phase I trial enrolling volunteers, and two more vaccine platforms in the pipeline: that's the machinery of pandemic preparedness grinding into gear. The question, as always, is whether it's grinding fast enough.
Deals & M&A
4 min read
Big Pharma Can't Stop Shopping in China
Chinese biotech companies inked $110 billion in out-licensing deals in just six months, a record that puts 2026 on pace to demolish last year's total. Every major Western pharma company is now shopping in China, and the carts keep getting bigger.
